SEARCH

SEARCH BY CITATION

References

  • 1
    Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res. Treat. 2002; 76; 2736.
  • 2
    Parl FF, Schmidt BP, Dupont WD, Wagner RK. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984; 54; 22372242.
  • 3
    Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol. 1988; 6; 10761087.
  • 4
    Crowe JP Jr, Gordon NH, Hubay CA et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg. Gynecol. Obstet. 1991; 173; 273278.
  • 5
    Aaltomaa S, Lipponen P, Eskelinen M et al. Hormone receptors as prognostic factors in female breast cancer. Ann. Med. 1991; 23; 643648.
  • 6
    Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J. Clin. Oncol. 2001; 19; 1827.
  • 7
    Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007; 9; R6.
  • 8
    Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl Cancer Inst. 1998; 90; 814823.
  • 9
    Nilsson S, Makela S, Treuter E et al. Mechanisms of estrogen action. Physiol. Rev. 2001; 81; 15351565.
  • 10
    Watanabe T, Inoue S, Ogawa S et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem. Biophys. Res. Commun. 1997; 236; 140145.
  • 11
    Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998; 54; 105112.
  • 12
    Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 1998; 51; 227238.
  • 13
    Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978; 103; 17421751.
  • 14
    Ravdin PM, Green S, Dorr TM et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 1992; 10; 12841291.
  • 15
    Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 2003; 21; 19731979.
  • 16
    Fuqua SA, Fitzgerald SD, Chamness GC et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991; 51; 105109.
  • 17
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 35; 14511467.
  • 18
    Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999; 17; 14741481.
  • 19
    Leake R, Barnes D, Pinder S et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J. Clin. Pathol. 2000; 53; 634635.
  • 20
    Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990; 50; 70577061.
  • 21
    Rhodes A, Jasani B, Balaton AJ et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am. J. Clin. Pathol. 2001; 115; 4458.
  • 22
    Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod. Pathol. 1999; 12; 827834.
  • 23
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235; 177182.
  • 24
    Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 2005; 353; 16521654.
  • 25
    Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol. 2001; 19; 23342356.
  • 26
    Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344; 783792.
  • 27
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006; 354; 809820.
  • 28
    Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005; 353; 16731684.
  • 29
    Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369; 2936.
  • 30
    Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006; 355; 27332743.
  • 31
    Pritchard KI, Shepherd LE, O’Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006; 354; 21032111.
  • 32
    Konecny GE, Thomssen C, Luck HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J. Natl Cancer Inst. 2004; 96; 11411151.
  • 33
    Prowell TM, Armstrong DK. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? Semin. Oncol. 2006; 33; 681687.
  • 34
    Dent R, Clemons M. Adjuvant trastuzumab for breast cancer. BMJ 2005; 331; 10351036.
  • 35
    Kroese M, Zimmern RL, Pinder SE. HER2 status in breast cancer – an example of pharmacogenetic testing. J. R. Soc. Med. 2007; 100; 326329.
  • 36
    Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 2004; 5; 6369.
  • 37
    Persons DL, Tubbs RR, Cooley LD et al. HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch. Pathol. Lab. Med. 2006; 130; 325331.
  • 38
    NHS Breast Screening Programme. Pathology reporting of breast disease. Sheffield, UK: NHS Cancer Screening Programmes and the Royal College of Pathologists, 2005.
  • 39
    Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing – National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst. 2002; 94; 852854.
  • 40
    Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 2003; 199; 418423.
  • 41
    Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747752.
  • 42
    Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. U. S. A. 2003; 100; 84188423.
  • 43
    Van De Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002; 161; 19911996.
  • 44
    Ellis IO, Bartlett J, Dowsett M et al. Best Practice No. 176: updated recommendations for HER2 testing in the UK. J. Clin. Pathol. 2004; 57; 233237.